What Human Dose-Response Data Exist for BPC-157 in Inflammatory Bowel Disease and Soft-Tissue Injury in 2026?

As of 2026, the human dose-response record for BPC-157 consists of a Phase 1 tolerability study in two healthy adults, an unpublished Phase 2 enema trial in ulcerative colitis, and a small number of soft-tissue case series. No dose-response curve has been established in humans for any indication. FDA reviewers characterised the available data as sparse, short, and exploratory.

What Was the PL14736 Clinical Programme, and What Doses Were Studied in Humans?

PL14736 was the clinical development designation for BPC-157 pursued by Pliva (Croatia) for inflammatory bowel disease. The programme advanced through a Phase 1 single-dose tolerability study in two healthy adults and a multicenter Phase 2 randomised, double-blind, placebo-controlled enema trial in mild-to-moderate ulcerative colitis. Full dose-response data from that trial have never been published.

The PL14736 designation covered at least three formulation iterations — PL-10, PLD-116, and PL14736 — reflecting successive pharmaceutical development attempts to stabilise BPC-157 for clinical delivery. The enema formulation was selected because rectal administration bypasses first-pass hepatic metabolism and delivers the compound directly to inflamed colonic mucosa, the primary target tissue in ulcerative colitis.

The Phase 1 component enrolled two healthy adult volunteers and evaluated single-dose tolerability and preliminary pharmacokinetics. No adverse effects were reported in either subject. However, a two-subject Phase 1 study cannot establish a dose-response relationship, define a maximum tolerated dose, or characterise pharmacokinetic variability across a population.

The Phase 2 multicenter trial enrolled patients with mild-to-moderate ulcerative colitis and administered BPC-157 enema at exploratory doses over a short treatment period. The trial was registered and conducted under controlled conditions. Its results were never published in a peer-reviewed journal, leaving the dose-response data — including which doses produced mucosal healing and what the safety profile looked like across dose groups — inaccessible to the scientific community.

Why Were the Phase 2 IBD Trial Results Never Published, and What Does This Mean for Dose-Response Knowledge?

The Phase 2 PL14736 results were never published, and no official explanation has been provided. This non-publication represents the single largest missing piece in BPC-157's human dose-response record: whatever dose-response signal was observed in a controlled human IBD population — positive, negative, or null — remains undisclosed and unavailable to the scientific community.

Publication bias in clinical research typically favours positive results. The non-publication of the PL14736 Phase 2 data could reflect a null or negative efficacy finding, a safety signal that discouraged further development, a commercial decision to abandon the IBD indication, or a regulatory interaction that halted the programme. Without access to the data, none of these explanations can be confirmed or excluded.

The 2026 Mateescu et al. review in Pharmaceutics (MDPI, 18(5):625) explicitly characterises the PL14736 programme as representing the only clinical investigations of BPC-157 in a gastrointestinal indication to date, and notes that these have not been followed by Phase 2 or Phase 3 trials with published results. This characterisation confirms that the IBD dose-response gap remains unresolved nearly two decades after the trial was conducted.

For practitioners and researchers, the non-publication means that the most relevant human dose-response dataset for BPC-157 in IBD — a controlled, randomised trial with defined dose groups — cannot be cited, replicated, or built upon. The scientific community is left with preclinical dose-response data and a Phase 1 tolerability observation in two subjects as the entirety of the published human IBD record.

What Preclinical Dose Ranges Produced IBD Effects, and How Do They Translate to Humans?

Preclinical BPC-157 research in rodent colitis models used doses spanning 10 ng/kg to 10 µg/kg administered intraperitoneally, subcutaneously, or orally, with both producing measurable reductions in inflammatory markers and mucosal healing parameters. This 1,000-fold effective dose range cannot be directly applied to humans: no allometric validation study has confirmed that these rodent doses scale predictably to human pharmacokinetics.

The rodent IBD dose-response literature consistently shows effects at both the nanogram-per-kilogram and microgram-per-kilogram ranges, suggesting a wide therapeutic window in preclinical models. Sikiric and colleagues documented BPC-157 at 10 µg/kg and 10 ng/kg producing comparable directional effects in cysteamine-induced colitis and intestinal anastomosis models. This finding implies either a very flat dose-response curve or a ceiling effect reached below the lower tested dose.

Allometric scaling from rat to human using body surface area conversion (FDA guidance factor of 6.2 for rat-to-human) places the human equivalent of the rodent 10 µg/kg dose at approximately 1.6 µg/kg in a 70 kg adult — roughly 112 µg total. The off-label human range of 200–500 µg/day cited in the 2026 Mateescu Pharmaceutics review substantially exceeds this allometric estimate, reflecting the absence of validated human PK data to anchor dose selection.

The critical limitation of preclinical-to-human dose translation for BPC-157 is the absence of a defined receptor. Standard allometric scaling assumes that receptor occupancy drives pharmacological effect and that receptor density scales predictably between species. BPC-157 has no confirmed receptor binding site, making receptor occupancy-based dose translation inapplicable and rendering allometric extrapolation particularly uncertain for this compound.

What Human Dose Data Exist for BPC-157 in Soft-Tissue Injury Contexts?

Human dose data for BPC-157 in soft-tissue injury are limited to uncontrolled case series and one registered but unpublished Phase 2 RCT (NCT07437547) in acute hamstring strain. The case series document administration at doses in the 200–500 µg range via subcutaneous injection, with no observed acute adverse events. No dose-response relationship has been characterised in any soft-tissue indication in humans.

The 2025 systematic review on emerging use of BPC-157 in orthopaedic sports medicine (PubMed 40756949) reviewed available human soft-tissue data and found that reported cases consistently used subcutaneous injection as the delivery route, with doses in the low-to-mid microgram range. The review noted that dose selection across these cases appeared to be based on extrapolation from preclinical data rather than any validated human dose-finding study.

Intra-articular administration has also been reported in case series involving knee osteoarthritis and post-surgical joint recovery. These cases document local injection of BPC-157 at doses not standardised across reports. No acute local adverse reactions — septic arthritis, synovial inflammation, or anaphylaxis — were attributed to BPC-157 in the reviewed cases. The absence of acute adverse events in small case series does not constitute a dose-response characterisation.

NCT07437547, the registered Phase 2 RCT in hamstring strain, represents the first formally controlled human dose-response study in a soft-tissue indication. Its design includes defined dose groups, a placebo comparator, and pre-specified pharmacokinetic endpoints. As of mid-2026, results remain unpublished. When published, this trial will provide the first controlled human data on BPC-157 dose-response relationships in soft tissue.

What Did FDA Reviewers Specifically Say About the Adequacy of BPC-157 Dose-Response Data?

FDA reviewers, in the July 2026 PCAC briefing materials, characterised the available human evidence for BPC-157 as sparse, short in duration, and based on exploratory doses not selected through validated dose-finding methodology. The committee explicitly noted the absence of a human dose-response curve as a primary barrier to establishing any rational dosing framework for compounding or clinical use.

The FDA's characterisation of the data as "exploratory" carries specific regulatory meaning. Exploratory doses are those selected without prior human pharmacokinetic data, typically based on preclinical extrapolation or clinical intuition. They do not constitute a validated dosing regimen because they have not been confirmed to produce target tissue concentrations, receptor engagement, or pharmacodynamic effects in humans at the doses administered.

The PCAC briefing noted that the PL14736 programme's Phase 1 data — two healthy adult subjects, single dose, no adverse events — satisfied none of the minimum requirements for a dose-response characterisation. A dose-response study requires multiple dose levels, a measurable pharmacodynamic endpoint, and sufficient subjects to detect dose-dependent variation. The PL14736 Phase 1 data meet none of these criteria.

The FDA's position, as reflected in the PCAC vote and the Category 2 compounding safety designation, is that the current human dose-response record does not support rational dose selection for BPC-157 in any indication. This is a statement about the evidentiary standard required before dosing can be considered clinically grounded, not a regulatory opinion about BPC-157's biological activity.

What Dose-Finding Studies Would Be Required to Establish a Human Dose-Response Relationship for BPC-157?

Establishing a human dose-response relationship for BPC-157 requires, at minimum: a first-in-human pharmacokinetic study across multiple dose levels establishing plasma concentration-time profiles; a dose-escalation study identifying the maximum tolerated dose; and indication-specific pharmacodynamic studies linking plasma concentrations to measurable tissue effects. None of these studies have been completed and published as of 2026.

A first-in-human PK study for BPC-157 faces compound-specific challenges. The rodent intravenous half-life is under 16 minutes, raising the question of whether subcutaneous or oral administration produces measurable plasma concentrations in humans at all, or whether local tissue effects dominate independently of systemic exposure. Resolving this requires sensitive analytical methods capable of detecting BPC-157 at low nanomolar concentrations against a complex plasma matrix.

The absence of a confirmed receptor also complicates pharmacodynamic endpoint selection. Standard dose-response studies use receptor occupancy or downstream biomarker changes as pharmacodynamic readouts. For BPC-157, candidate pharmacodynamic endpoints include serum VEGF, nitric oxide metabolites, or tissue-specific healing markers — but none have been validated as surrogate endpoints in human studies.

For the IBD indication specifically, validated pharmacodynamic endpoints exist — endoscopic mucosal healing scores, faecal calprotectin, and histological inflammation indices are all established in IBD clinical trials. A BPC-157 dose-finding study in IBD could apply these endpoints directly, which is one reason the IBD indication remains the most tractable pathway for generating human dose-response data. The non-publication of the PL14736 Phase 2 data represents a missed opportunity to establish exactly this kind of endpoint-linked dose-response characterisation.

How Is BPC-157 Currently Studied in Human Protocols, and What Dose Parameters Are Used?

Current human BPC-157 research protocols use doses in the 200–500 µg range for subcutaneous administration and low-microgram enema doses for gastrointestinal applications, all derived from preclinical extrapolation rather than validated human PK data. No protocol can be described as evidence-based in the dose-selection sense until human pharmacokinetic data confirm target tissue exposure at the administered dose.

The table above reflects the complete published human dose record for BPC-157 as of mid-2026. Across all indications and routes, no study has generated a validated dose-response curve in human subjects. The NCT07437547 trial is the only ongoing controlled study with the design capacity to produce dose-response data, and its results remain pending.

Safety Considerations: What the Absence of Human Dose-Response Data Means for Clinical Practice in 2026

The absence of a validated human dose-response curve for BPC-157 means that any dose used outside a registered clinical trial is empirically unanchored. Practitioners cannot confirm that a given dose produces therapeutic tissue concentrations, stays below a maximum tolerated threshold, or avoids pharmacodynamic interactions with co-administered medications. This is a patient safety issue, not merely a regulatory formality.

The practical consequence of absent dose-response data is that practitioners using BPC-157 outside a clinical trial have no validated basis for dose selection, dose adjustment, or dose cessation. The 200–500 µg/day range cited in off-label contexts is derived from allometric scaling of rodent data — a methodology that carries substantial uncertainty for peptides without confirmed receptors and without human PK validation.

Patients with inflammatory bowel disease represent a population of particular concern. IBD patients frequently use immunosuppressants, biologics, and aminosalicylates — drug classes with potential pharmacodynamic overlap with BPC-157's anti-inflammatory and pro-angiogenic mechanisms. Without human dose-response data, the interaction profile between BPC-157 and these agents cannot be characterised, and dose adjustments to manage interactions cannot be rationally designed.

Practitioners considering BPC-157 in any context must document that patients have been informed of the following: no validated human dose exists; the available human data consist of a two-subject Phase 1 tolerability observation and an unpublished Phase 2 trial; the FDA has formally characterised the evidence as sparse, short, and exploratory; and the only ongoing controlled human dose-response study has not yet published results. For cross-reference on the broader safety risk categories associated with BPC-157, see What Are the Known Safety Risks and Dose Limits for BPC-157 in Humans in 2026? on this site. For the mechanistic basis of BPC-157's preclinical activity, see BPC-157 Mechanisms and Tissue Repair: A 2026 Clinical Monograph on Peptides Know How. What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears? What Does 2026 Research Reveal About BPC-157 for Musculoskeletal Healing — Regeneration or Risk? What Did the July 2026 FDA PCAC Review Conclude About BPC-157's Biopharmaceutical Data Gaps and 503A Compounding Eligibility?